Should the federal government provide a non-mRNA vaccine for COVID-19 this respiratory virus season?
The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. to get the shot.
In the first of a double dose of wins for US biotech Novavax, the company has been granted full marketing authorisation (MA) by the European Commission in the EU for Nuvaxovid (NVX-CoV2373 ...
The product, called Nuvaxovid, is a protein-based vaccine. Health Canada said the vaccine was updated to target the JN.1 variant, an offshoot of Omicron. Nationally, the JN.1 group is ...
Currently, the KP.3 and KP.3.1.1 FLiRT variants, derivatives of KP.1 and KP.2, are the most prevalent in Canada and the ...
Dr Clive Dix said that Nuvaxovid has excellent clinical data and – as a it has good stability at fridge temperatures – could be easily rolled out with the flu vaccine next winter, and should ...
The protein-based vaccine, called Nuvaxovid, targets the JN.1 subvariant of Omicron, replacing the previous version which targeted the XBB.1.5 Omicron subvariant, the agency said in an online update ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback